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Attention Deficit Hyperactivity 
Disorder and Blood Lead 
Levels in Chinese Children
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In their study of the relationship of blood 
lead levels (BLLs) in children 4–12 years 
of age and attention deficit hyper  activity 
disorder (ADHD), Wang et al. (2008) con-
sidered potential confounding variables and 
covariates with considerable thoroughness. 
For certain of these (e.g., low birth weight), 
the proportion of affected children gener-
ally accords well with reported prevalence in 
other settings [UNICEF and World Health 
Organization (WHO) 2004]. However, this 
was not so with case children with a family 
history of ADHD described by Wang et al. 
(2008). Only 21 (3.3%) of the 630 cases in 
their study had such a history. 
ADHD and other externalizing dis  orders 
(e.g., conduct disorder) are known to have 
substantial genetic components, and ADHD 
heritability has been estimated to be 75% 
(Biederman and Faraone 2005; Gelhorn et al. 
2006). Among children with ADHD or ear-
lier definitions of the disorder, the reported 
proportions with at least one affected parent 
or sibling range from 9% to 64% (Biederman 
2005; Biederman et al. 1990, 2008; Milberger 
et al. 1998; Roizen et al. 1996; Schachar and 
Wachsmuth 1990). This substantial body of 
work suggests a figure of 20–25% as a reason-
able estimate of the proportion of first-degree 
relatives afflicted with ADHD, or 6–8 times 
that reported by Wang et al. (2008) in the 
families of their case children. 
Wang et al. (2008) assessed family history 
of ADHD by psychiatric diagnoses noted in 
clinical reports. It is possible that such infor-
mation was not systematically acquired in 
previous years and is thus under  represented 
in these reports. This would actually be likely 
if ADHD was less well-defined or considered 
less often as a diagnosis in Anhui Province, 
China, when the parents of the 4- to 12-year-
old children included in this study were of 
similar age. It is also possible that ADHD 
in this setting differed in some way from 
ADHD in other settings, although the rigor-
ous diagnostic criteria used by the authors 
make this explanation less plausible.
In their backward stepwise logistic model 
(their Table 3), Wang et al. (2008) showed 
that ADHD in the child is positively asso-
ciated with family history of ADHD and 
BLL (≥ 10 µg/dL vs. ≤ 5 µg/dL and 5–10 µg/
dL vs. ≤ 5 µg/dL) and inversely associated 
with maternal education. Assuming that the 
reported odds ratio of 5.65 for family history 
of ADHD remained unaltered, a 6- to 8-fold 
increase in the number of case children with 
this exposure would commensurately increase 
the relevant Wald statistic and almost cer-
tainly reduce the Wald statistics of the associ-
ations with BLL and/or maternal education, 
conceivably to non  significant levels. 
Wang et al. (2008) stated that their results 
reinforce findings from two previous studies 
of the relationship of BLL to ADHD, but it 
is unclear how this is so (Braun et al. 2006; 
Nigg et al. 2008). In the study by Braun et al. 
(2006), the cut-point of the highest BLL 
exposure quintile, the only one associated 
positively and significantly with ADHD, was 
2 µg/dL; in the study by Nigg et al. (2008), 
the mean BLL for the ADHD-combined 
group was 1.26 µg/dL. Yet the mean BLL in 
control children studied by Wang et al.—by 
definition, ADHD-free—was 5.76 µg/dL, 
nearly 3 times the level reported by Braun 
et al. and 5 times that of Nigg et al. In neither 
of the earlier studies did the researchers adjust 
the BLL–ADHD relationship for family his-
tory of ADHD.
Familial transmission of ADHD and its 
diagnostic forebears has been documented 
for more than three decades (Cantwell 
1972), and systematic assessment of the 
contribution of familial inheritance has 
been under way for more than two decades 
(Biederman 1986). Studying risk factors for 
ADHD with incomplete or no control of 
family history of ADHD is like studying 
risk factors for lung cancer with inadequate 
control of smoking history (Stevens and 
Moolgavkar 1984). Doing so may answer 
some questions, but the main question 
remains unanswered.
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Editor’s note: In accordance with journal 
policy, Wang et al. were asked whether they 
wanted to respond to this letter, but they chose 
not to do so.
Cancer Risk and GSTM1 and 
GSTT1 Polymorphisms
doi:10.1289/ehp.0900829
Rossi et al. (2009) stated in their conclu-
sion that “GSTM1 [gluta  thione S-transferase 
M1] and GSTT1 [gluta  thione S-transferase 
theta 1]poly  morphisms [as all individual 
polymorphisms] … are not expected to 
have a dramatic influence on baseline CA 
[chromo  somal aberration] or overall cancer 
risk.” 
We agree with these statements from a 
general point of view. However, it is one 
thing to suggest that an evident pathologic 
marker, such as CA frequency in peripheral 
lympho  cytes, could be an expression of can-
cer (like elevated carcino  embryonic antigen 
or other biomarkers) and another to exclude 
any influence of a genetic polymorphism on 
the occurrence of a specific type of cancer on 
the basis of a study that is basically not suit-
able to answer the question. 
The correspondence section is a public forum and, as such, is not peer-reviewed. EHP is not responsible 
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We will not address the advantages of the 
Bayesian approach versus the classic frequen-
tist model. However, as clinicians, we would 
like to comment on epidemiologic studies 
on cancer, in particular those concerning the 
possible effects of complex causa  tive factors 
such as environmental pollution. We also 
will discuss issues concerning patients and 
outcomes of the article by Rossi et al. (2009). 
In particular, we will focus on issues that 
are often considered by epidemiologists and 
those interested in statistical analysis to be 
pathophysiologic or pathogenetic details, but 
are, on the contrary, basic issues for those 
examining clinical and pathological findings. 
Although the combination of bone and 
skin cancers (cancers that originate from dif-
ferent tissues and are related to completely 
different patho  genetic agents and patho-
physiologic mecha  nisms) could be accept-
able from a statistical point of view, this 
practice creates a methodologic bias from 
pathophysiologic and pathogenetic points of 
view. Because Rossi et al. (2009) included a 
large number of bone and skin cancer cases 
in their study (n = 20 in their Table 2), it is 
of paramount importance to state whether 
cyto  chrome P451 A1 (CYP1A1) is a basic 
factor in the occurrence of these cancers. For 
lung and respiratory tract cancer, the role 
of CYP1A1 has been tested; however, it is 
not appropriate to use these polymorphisms, 
which are specific for the metabolism of some 
xenobiotics, as a marker of all cancers. 
Our team has long been involved in the 
detection of cause and effect relationships 
between presumed causative factors and can-
cer, in particular, concerning the relative role 
of inherited predisposition and environmen-
tal factors, the relative impact of intrinsic 
toxicity or carcinogenicity, and the role of 
host susceptibility and response (Cetta et al. 
2007, 2009a). 
In a genome-wide analysis of copy num-
bers in couples in which either husbands had 
been occupationally exposed to asbestos but 
did not have mesothelioma or spouses with 
mesothelioma who had not been occupation-
ally exposed to asbestos, we reported a panel 
of differently expressed genes that could be 
responsible for a different inherited suscep-
tibility. This panel of differently expressed 
genes sometimes included genes involved in 
the control of major histo  compatibility sys-
tems, in the production of drug-metaboliz-
ing enzymes, or of X-ray repair or mismatch 
repair genes (Cetta F. Dhamo A, Zangari R, 
unpublished data). 
Therefore, it is plausible that genetic 
polymorphisms in GSTM1 and GSTT1 may 
be part (if not the main determinant) of a 
panel of genes that define the individual sus-
ceptibility of some subjects to inter  act differ-
ently with a given environmental agent; this 
interaction would lead to cancer as a final 
outcome only in the susceptible individuals 
and not in others, even if the nonsusceptible 
individuals are more exposed to the same 
toxic or carcinogenic agent. 
We suggest that the pathogenetic task 
(i.e., a better knowledge of the variable 
impact of the same toxic agent on differ-
ent individuals) requires very specific and 
focused studies and not generic studies that 
combine skin and bone cancer grouped by 
the same code.
We suggest that studies rely less on the sta-
tistical power of numbers (cases and controls) 
and pay more attention to the homo  geneity of 
populations, groups, or subgroups. These stud-
ies should focus not only on the biological but 
also on the pathophysiologic and pathogenetic 
plausibility of observed data; they should avoid 
mixing “apples and oranges.” 
We suggest that researchers examine data 
carefully before they state that one event is 
influenced or not influenced by a causative or 
facilitating agent, namely when inter  actions 
between cause and effect are very complex 
and the causative relationship is not clear-cut 
(Cetta et al. 2007, 2009b). This is even more 
important when attempting to establish the 
relative impact of inherited or environmental 
factors in the occurrence of various types of 
cancers, each of which has its own peculiarity 
and wide variations, even within the range 
of tumors affecting the same organ or tissue 
(Cetta et al. 2007, 2009a). 
In the future, there will be a major need 
for improved knowledge of causa  tive and 
patho  physiologic mechanisms and for more 
strict adherence to this knowledge before 
designing epidemiologic or pathogenetic 
studies. These studies must rely more on the 
homo  geneity of the enrolled population and 
on the direct cause and effect relationship 
between the causative agent and the expected 
outcome, and less on the number of enrolled 
subjects (if subjects are not appropriate for the 
scope of the study, their inclusion is poten-
tially misleading. Panel studies in smaller but 
well-selected groups will give more useful 
information than large population studies that 
are missing the patho  physiologic and causative 
targets, in particular when large studies are 
based on too many inferences and/or extrapo-
la  tions from old or inhomogeneous data. 
This work was supported by the Flagship 
Project, PROLIFE, City of Milan, Italy.
The authors declare they have no competing 
financial interests.
Francesco Cetta*
Armand Dhamo 
Laura Moltoni
Rosalia Zangari
Department of Surgery
Research Doctorate in Oncology and Genetics
University of Siena
Siena, Italy
*PAT Geriatric Institute, Milan, Italy
E-mail: cetta@unisi.it
Re f e R e n c e s
Cetta F, Dhamo A, Azzarà A, Moltoni L. 2009a. The role of 
inherited predisposition and environmental factors in the 
occurrence of multiple different solid tumors in the same 
individual. The experience of the University Hospital of 
Siena. In: Multiple Primary Malignancies (Renda A, ed).   
Milan:Springer Verlag, 157–178. 
Cetta F, Dhamo A, Moltoni L, Bolzacchini E. 2009b. Adverse 
health effects from combustion derived nanoparticles: 
the relative role of intrinsic particle toxicity and host 
response [Letter]. Environ Health Perspect 117:A190. 
Cetta F, Dhamo A, Schiraldi G, Camatini M. 2007. Particulate 
matter, science and European Union policy. Eur Respir J 
10:805–806.
Rossi AM, Hansteen IL, Skjelbred CF, Ballardin M, Maggioi V, 
Murgia E, et al. 2009. Association between frequency of 
chromosomal aberrations and cancer risk is not influ-
enced by genetic polymorphisms in GSTM1 and GSTT1. 
Environ Health Perspect 117:203–208.
Cancer Risk and GSTM1 and 
GSTT1 Polymorphisms:
Hansteen et al. Respond
doi:10.1289/ehp.0900829R
We thank Cetta et al. for the interesting 
comments regarding our article (Rossi et al. 
2009). In their letter they address two main 
issues. The first refers to the role of genetic 
polymorphisms in the causal relationships 
between exposure to carcinogens and cancer 
occurrence. The second is more conceptual 
and criticizes the evolution of association 
studies, claiming a decreased attention to 
pathogenetic mechanisms in favor of an 
indiscriminate increase of the study size, with 
a consequent lack of biological   plausibility.
We agree that these are important issues. 
We have addressed the problem of inherited 
predisposition for DNA damage from a dif-
ferent angle, namely using the frequency of 
chromosomal aberration (CA) as a response 
indicator for occupational and environmen-
tal exposure to genotoxic agents. An increase 
in CA level in exposed individuals compared 
with controls has been documented since the 
1990s (Nordic Study Group 1990). The con-
ceptual basis for using this assay has been the 
hypothesis that the extent of genetic damage in 
peripheral lymphocytes reflects critical events 
for the carcinogenic process in target tissues. 
The key issue—whether the association 
with cancer risk is attributable to exposure 
to carcinogenic agents or reflects inherited 
susceptibility and accumulated damages—
was addressed with a nested case–control 
study on incident and deceased cancer cases 
in the Nordic and Italian cohorts (Bonassi 
et al. 2000). The main findings of that study 
indicated an increase in cancer risk for sub-
jects with high CA levels compared with those 
with low levels. This increase was independent A 288  v o l u m e  117 | n u m b e r  7 | July 2009  •  Environmental Health Perspectives
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of exposure history, as further verified in fol-
low-up studies (Bonassi et al. 2008; Hagmar 
et al. 2004).  
In all these studies, cancer has been stud-
ied as one entity. This summarization was 
mostly due to statistical needs, although the 
very early occurrence of chromosome damage 
in the carcinogenic pathway of most solid can-
cers provided a valuable rationale (Mitelman 
et al. 2004). A further reason for summarizing 
data by cancer type was that damages were 
measured in surrogate tissues and not in the 
target, providing only an indirect measure of 
cancer-related events. However, studying the 
cancer site in relation to CA frequency was a 
major interest of our group, because different 
types of cancers have different patho  genetic 
models. In our recent article (Rossi et al. 
2009), we grouped cancer types into three 
groups, and we showed for all of these groups 
that subjects with high levels of CAs are more 
susceptible to developing cancer than are sub-
jects with low or medium levels of CAs; this 
indicates that CA is an inherited susceptibility 
marker for cancer regardless of cancer type.
The beginning of Cetta et al.’s letter is 
misleading. The statement from our article 
(Rossi et al. 2009) that “GSTM1 [gluta-
thione S-transferase M1] and GSTT1 [gluta-
thione S-transferase theta 1]polymorphisms 
[as all individual polymorphisms] . . . are 
not expected to have a dramatic influence 
on baseline CA [chromosomal aberration] 
or overall cancer risk” is not a conclusion 
of the study, but describes the conclusions 
of the extensive litera  ture supporting this 
evidence (Hirschhorn 2009). We agree that 
it is important to examine the cause of dif-
ferent types of cancer and the role(s) of the 
different modifying enzymes, including 
GSTM1 and GSTT1. However, the present 
study was designed to evaluate a possible 
modifying effect of GSTM1 and GSTT1 
on the cancer predictivity of CA (indicat-
ing individual susceptibility to developing 
cancer). Our main concern was identify 
individuals more susceptible to damage 
from known genotoxic exposure. Because 
only GSTM1 and GSTT1 polymorphisms 
have been extensively evaluated in human 
surveillance studies, we tested only these 
genotypes. Within the consortium of stud-
ies included in this project (Bonassi et al. 
2008), further follow-up studies to differen-
tiate cancer types or include other genotypes 
are possible, providing adequate financial 
support.
The issue raised by Cetta et al. of 
decreased attention to patho  genetic mecha-
nisms in favor of larger studies, with a con-
sequent lack of biological plausibility, is only 
partially correct. Actually, in association stud-
ies that link a genetic poly  morphism to the 
effect of exposure or to the risk of cancer, the 
lack of specificity is the main reason for fail-
ure. Another reason for their failure is small 
study size, which generates meaningless and 
often contrasting results. The conflict noted 
by Cetta et al. is apparent because, as demon-
strated by the success of genome-wide asso-
ciation studies, the need of reaching a proper 
statistical power is as important as studying a 
genetic poly  morphism in a specific pathway.
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Modern Environmental Health 
Hazards in Africa: Additional 
Comments
doi:10.1289/ehp.0900669
I commend Environment Health Perspectives 
for publishing the work of Nweke and 
Sanders (2009); this significant contribu-
tion brought to light interesting aspects of 
environmental health hazards on the African 
continent that can be universalized for 
scien  tifically unrepresented less developed 
countries and regions of the planet. In this 
dimension, existing studies [World Health 
Organization (WHO) 1989] of that conti-
nent compel us to share additional results 
of studies of heavy metals (mercury, lead, 
and cadmium) related to early exposure in 
children. I would like to address the WHO 
(1989) study of breast milk concentrations 
used to monitor mother–infant contamina-
tion in selected African countries (Nigeria 
and Zaire). I would also like to point out an 
often neglected but universal source of Hg 
exposure during pregnancy and throughout 
infancy and childhood—ethylmercury (etHg) 
in thimerosal-containing vaccines (TCVs). 
Concentrations of Hg and Pb in breast 
milk are important indicators of prenatal 
exposure, the period when most neurotoxic 
insults of these elements occur. In a review in 
which I summarized the WHO (1989) study, 
I showed that mean Hg concentrations were 
similar in both Nigeria and Zaire (Dórea 
2004), but these concentrations were among 
the highest reported in that review (Dórea 
2004). However, the concentrations of milk 
Pb were higher than that of milk Hg for both 
countries; in the case of Pb, mean Pb con-
centrations in rural Zairians were twice that 
of urban dwellers. On a molar basis, there 
was twice as much Pb as Hg in these African 
countries (Dórea 2004); however, the ratios 
of Se and Ca concentrations (attenua  tors of 
neurotoxicity of Hg and Pb) were quite dif-
ferent between the two countries.
Nweke and Sanders (2009) realized that 
the earliest stages of neurodevelopment are 
most vulnerable to the toxic effects of Hg. 
Therefore, I find the figures of occupational 
exposure involving mothers to be disturb-
ing; women occupationally exposed to gold 
processing from amalgam range from 5% 
of the population in South Africa to 50% in 
Mali. Also, African women are exposed to 
Hg in soap and through traditional fish con-
sumption. However, Nweke and Sanders 
(2009) did not mention that tetanus vac-
cines are used in countries following WHO 
recommendations to control or eradi  cate 
maternal and neonatal tetanus. These vac-
cines are preserved with thimerosal. In any 
part of the developing world where TCVs 
are in widespread use, a newborn is exposed Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r  7 | July 2009  A 289
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to high concentrations of etHg depending on 
the child’s weight and vaccine brand (Dórea 
and Marques 2008). Indeed, because the 
hepatitis-B vaccine is given within hours of 
birth, Hg concentrations can reach extremely 
high levels of acute exposure, depending 
on birth weight and vaccine manufacturer 
(Dórea and Marques 2008). These expo-
sures are higher than the ones estimated for 
occupationally exposed mothers working 
with gold extraction (Dórea 2009). Nweke 
and Sanders (2009) covered environmental 
hazards as a result of exposure to hazard-
ous pollutants in tandem with development 
activities, as well as evidence of their adverse 
effects on African populations. However, 
they did not mention this important source 
of Hg exposure to which the fetus (during 
pregnancy), infant, or child is exposed. 
Some African populations, due to lack 
of sanitation and hygiene, are more prone to 
preventable diseases and are, as a result, a tar-
get for vaccination campaigns for children’s 
diseases; additionally, emergency measures 
may introduce specific vaccines for diseases 
that are rare (or non  existent), eradicated, or 
controlled in other countries. Some of these 
vaccines, for operational reasons, need thi-
merosal as a preservative. Currently, because 
of the low cost, TCVs are routinely used 
in under  developed countries, whereas the 
European Union, the United States, and 
other industrialized countries have stopped 
using them based on the plausibility that 
TCVs may affect neuro  development of 
young children. These precautionary meas-
ures need to reach the great majority of 
infants and young children around the world 
(including Africa).
Given the heterogeneous socioeconomic 
situation of African countries, differences 
in need for vaccines and the affordability of 
mass immunization programs are complex 
and difficult to study. Although I support 
mass vaccination, it is important to take into 
account characteristics of the health status of 
African populations that put groups at risk 
because of their increased suceptibility to Hg 
neuro  toxicity. As recognized by Nweke and 
Sanders (2009), Africa’s environmental health 
issues are complex; the environmental health 
policies and actions of the continent should 
be comprehensive, holistic, and popu  lation 
specific in the identification, recog  nition, and 
manage  ment of environmental health haz-
ards. Additionally, the transition to address-
ing modern environmental health hazards in 
Africa is also occurring in other parts of the 
world that have a similar combination of pre-
industrial and industrial era environmental 
health issues combined with the disease bur-
den of children.
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Editor’s note: In accordance with journal 
policy, Nweke and Sanders were asked whether 
they wanted to respond to this letter, but they 
chose not to do so.